Nicox and Sequenom announce the launch of expanded access to RetnaGene™ test portfolio in the U.S.

June 19, 2014.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox’s subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual’s risk for advanced age-related macular degeneration (AMD).

Read more

At a glance

Nicox Ophthalmic Diagnostics is committed not only to providing advanced diagnostics and therapeutics for eye care professionals, but even more important, to helping improve quality of life for patients.

Nicox is headquartered in Sophia Antipolis (Nice, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX). North American operations are based in Fort Worth (Texas, United States) and research capabilities in Bresso (Milan, Italy).

Key figures

18 years of experience in pharmaceutical R&D

253 patents granted

150 employees worldwide

6 sales operations offices: UK, France, Italy, Spain, Germany and USA

2012 is the year when Nicox became a specialized ophthalmic company